MedTrace Logo

Synergistic Effect of Plasmid Inhibitors and Antimicrobial Drugs Against Clinical MDR-hvKP

NCT05932355 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-07-06

No results posted yet for this study

Summary

1. Screening for MDR-hvKP causing VAP in patients admitted to chest ICU in Assiut University Hospital.
2. In vitro evaluation of the synergistic activity of combined meropenem/levofloxacin with and without kasugamycin against clinical MDR-hvKP isolates by checkerboard and time killing assay.
3. In vivo evaluation of the synergistic activity of combined meropenem/levofloxacin with and without kasugamycin using MDR-hvKP septic rat model.

Conditions

  • Synergy Between Plasmid Inhibitors and Combined Antibiotics

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Sherine Aly, Professor · Department of Microbiology and Immunology

  • Wegdan Mohamad, Assistant Professor · Department of Microbiology and Immunology

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2025-07-31
Completion
2025-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05932355 on ClinicalTrials.gov